Literature DB >> 26821251

(-)-β-hydrastine suppresses the proliferation and invasion of human lung adenocarcinoma cells by inhibiting PAK4 kinase activity.

Bingyu Guo1, Xiaodong Li1, Shuai Song2, Meng Chen1, Maosheng Cheng2, Dongmei Zhao2, Feng Li1.   

Abstract

(-)-β-hydrastine is one of the main active components of the medicinal plant, Hydrastis canadensis, which is used in many dietary supplements intended to enhance the immune system. However, whether (-)-β-hydrastine affects the tumor signaling pathway remains unexplored. In the present study, we found that (-)-β-hydrastine inhibited the kinase activity of p21-activated kinase 4 (PAK4), which is involved in the regulation of cytoskeletal reorganization, cell proliferation, gene transcription, oncogenic transformation and cell invasion. In the present study, (-)-β-hydrastine suppressed lung adenocarcinoma cell proliferation by inhibiting expression of cyclin D1/D3 and CDK2/4/6, leading to cell cycle arrest at the G1 phase, in a PAK4 kinase-dependent manner. Moreover, inhibition of PAK4 kinase activity by (-)-β-hydrastine also promoted the early apoptosis of lung adenocarcinoma cells through the mitochondrial apoptosis pathway. In addition, (-)-β-hydrastine significantly suppressed the migration and invasion of human lung adenocarcinoma cells in conjunction with concomitant blockage of the PAK4/LIMK1/cofilin, PAK4/SCG10 and PAK4/MMP2 pathways. All of these data indicate that (-)-β-hydrastine, as a novel PAK4 inhibitor, suppresses the proliferation and invasion of lung adenocarcinoma cells. Taken together, these results provide novel insight into the development of a PAK4 kinase inhibitor and a potential therapeutic strategy for lung cancer.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26821251     DOI: 10.3892/or.2016.4594

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  5 in total

1.  Studies on asymmetric total synthesis of (-)-β-hydrastine via a chiral epoxide ring-opening cascade cyclization strategy.

Authors:  Jihui Li; Tianxiao Wu; Xinjing Song; Yang Zheng; Jiaxin Meng; Qiaohua Qin; Yongxiang Liu; Dongmei Zhao; Maosheng Cheng
Journal:  RSC Adv       Date:  2020-05-19       Impact factor: 4.036

Review 2.  Nano-Drug Delivery Systems Entrapping Natural Bioactive Compounds for Cancer: Recent Progress and Future Challenges.

Authors:  Vivek P Chavda; Aayushi B Patel; Kavya J Mistry; Suresh F Suthar; Zhuo-Xun Wu; Zhe-Sheng Chen; Kaijian Hou
Journal:  Front Oncol       Date:  2022-03-29       Impact factor: 6.244

3.  Interfering with pak4 Protein Expression Affects Osteosarcoma Cell Proliferation and Migration.

Authors:  Yuxin Fu; Lun Fang; Qipu Yin; Qi Wu; Wei Sui; Ying Sun; Xindi Zhao; Yadi Wu; Lu Zhou
Journal:  Biomed Res Int       Date:  2021-12-30       Impact factor: 3.411

4.  Gene-set Analysis with CGI Information for Differential DNA Methylation Profiling.

Authors:  Chia-Wei Chang; Tzu-Pin Lu; Chang-Xian She; Yen-Chen Feng; Chuhsing Kate Hsiao
Journal:  Sci Rep       Date:  2016-04-19       Impact factor: 4.379

5.  Effects of PAK4/LIMK1/Cofilin-1 signaling pathway on proliferation, invasion, and migration of human osteosarcoma cells.

Authors:  Zhi-Feng Li; Yin-Di Yao; Yin-Yin Zhao; Yan Liu; Zhen-Hua Liu; Pei Hu; Zhuo-Ran Zhu
Journal:  J Clin Lab Anal       Date:  2020-05-28       Impact factor: 2.352

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.